Clinical Trial Search

Primary: Number of Participants With Serious and Non-Serious Adverse Events — 4; 5; 4 Participants

Primary: Number of Participants With Overall Response — 7; 5 Participants

Primary: The Brief Repeatable Battery of Rao — 42.09; 35.5 Correct words — p=0.028

Primary: Number of Participants With and Without Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Non-depolarizing Neuromuscular Blocking Agent (NMBA)…

Primary: Number of Participants With Dose-Limiting Toxicity — 0; 1; 0; 0 Participants

Primary: Percentage of Participants With Time to First Occurrence of Primary Efficacy Endpoint (Composite and Components) — 8.79; 5.95; 1.90; 2.14 Percentage of participants…

Primary: Number of Participants With Overall Response — 4; 4 Participants

Primary: Incidence of Respiratory Adverse Events of Special Interest (RAESIs) — 10; 7 Participants

Primary: Part 1: Area Under the Concentration-time Curve (AUC) From Time Zero Time (Pre-dose) to the Time of Last Quantifiable Concentration (AUC[0-t]) of Levocetirizine…

Primary: Number of Patients With a Surgical Site Infection — 10; 13 Participants

Primary: Number of Participants for Which the Surgeon Changed Reduction of Syndesmotic Reduction Because of Information Provided by 3D Fluoroscopy — 14 Participants

Primary: Number of Participants With Adverse Events During the Procedure and up to 30 Days Following Procedure — 5 Participants

Primary: Functional Outcome as Measured by the Activities Scale for Kids at 4 Weeks From the Time of the Initial Injury — 85.3; 91.3 percentage of questions

Primary: Change in Glucose Control (Stage 1: Usual Care v. Peer Mentoring) — -0.1978; -0.5246 percent — p=0.0611

Primary: Effect of Entacapone on Methamphetamine-induced Mood — 12.500; 13.750; 7.500; 9.833 units on a scale